The FDA issued two revised draft guidances today relating to over-the-counter and prescription blood glucose monitors.
The new documents, which are intended to update guidances issued in 2016, were based on feedback from stakeholders, who requested more clarification on design considerations and recommended standards, according to the U.S. regulatory agency.
Get the full story at our sister site, Drug Delivery Business News.